BioSpace | The biopharma industry must become more efficient. Whether this comes from successive iterations, a revelation borne from pandemic-enabled efficiencies or consequences of the Inflation Reduction Act of 2022, efficiency has become a biopharma industry imperative. Continue Reading….
Healthcare Tech Outlook | Genomenon, Inc, an AI-driven genomics company, announced today that Dr. Sam Globus has been appointed vice president of operations. To support Genomenon’s goal to curate the entire human genome, Globus will manage the rapid growth of the company’s data science and variant curation work. Continue Reading….
GenomeWeb | Genomenon said this week that it has integrated all the variants and pathogenicity interpretations from the US National Institutes of Health’s ClinVar database into its artificial intelligence-based Mastermind Genomic Search Engine. With the integration, Mastermind users will no longer have to go outside the Genomenon platform to find information within ClinVar, and the search will incorporate ClinVar data alongside other results. Continue Reading….
LabPlus | Artificial intelligence (AI) genomics company Genomenon has integrated patient variant data from the National Institutes of Health’s (NIH) ClinVar database into its Mastermind Genomic Search Engine. Continue Reading….
August 25, 2022 – BeginNGS Program Seeks to Improve Pediatric Rare Disease Dx, Treatment via Rapid NGS, Data Curation
GenomeWeb | In a paper published this week in the American Journal of Human Genetics, collaborators led by the Rady Children’s Institute for Genomic Medicine (RCIGM®) formally spelled out plans to improve detection and treatment of rare hereditary pediatric diseases through rapid whole-genome sequencing (rWGS). Continue Reading….
August 24, 2022 – BeginNGS Program Seeks to Improve Pediatric Rare Disease Dx, Treatment via Rapid NGS, Data Curation
American Association for the Advancement of Science (AAAS) | Rady Children’s Institute for Genomic Medicine (RCIGM®) today announced the publication of a peer-reviewed study in the American Journal of Human Genetics (AJHG) describing a scalable prototype for newborn screening (NBS) that includes the diagnosis of genetic diseases by rapid Whole Genome Sequencing (rWGS®) and virtual acute management guidance. Continue Reading….
GenomeWeb | Genomenon said Tuesday that it has been named the exclusive gene curation partner for Rady Children’s Institute for Genomic Medicine’s (RCIGM®) recently launched BeginNGS newborn screening panel. Ann Arbor, Michigan-based Genomenon said that it will curate all genes in the panel and deliver “comprehensive” data about variants within those genes to clinicians, with the goal of improving outcomes in infants with rare genetic diseases. Continue Reading….
Inside Precision Medicine | The results of a research project led by Rady Children’s Institute for Genomic Medicine (RCIGM) show that an automated, virtual disease management system that includes fast whole genome sequencing and analysis could help to manage genetic diseases better. The new GTRx prototype brings together different research streams and was completed with the help of industry partners Alexion, AstraZeneca, Fabric Genomics, Genomenon, Illumina, and SL Data Strategies, as well as Keck Graduate Institute, Rady Children’s Hospital–San Diego, and UC San Diego departments of Pediatrics and Neuroscience. Continue Reading….
July 26, 2022 – Study supports potential of genome-to-treatment to guide physicians in the management of 500 genetic diseases
Medical Xpress | Rady Children’s Institute for Genomic Medicine (RCIGM) today announced the publication of a study in Nature Communications describing and examining the performance of Genome-to-Treatment (GTRx), an automated, virtual disease management system that integrates a rapid Whole Genome Sequencing (rWGS) diagnosis completed in 13.5 hours with a custom lab information management system and analysis pipeline. Continue Reading….
July 25, 2022 – The earlier the better: New consortium leverages infant screening to accelerate treatment
PharmaVoice | Newborn screening is gaining prominence across the biopharma and healthcare industries amid efforts to detect and treat disease as early as possible. With projections that there could be as many as 60 breakthrough cell and gene therapies approved by the FDA over the next 10 years, the race is on to bring newborn screening practices up to speed. Continue Reading….
LabPlus | Rady Children’s Institute for Genomic Medicine (RCIGM) has launched a program that aims to advance newborn screening for treatable genetic diseases through rapid whole-genome sequencing. RCIGM said it is evaluating the scalability of a diagnostic and precision medicine guidance tool called BeginNGS. Continue Reading….
Inside Precision Medicine | Already well known for its groundbreaking effort to rapidly diagnose and treat newborn children with rare, often life-threatening diseases, Rady Children’s Institute for Genomic Medicine (RCIGM) announced it has launched a novel program to evaluate the scalability of new diagnostic and precision medicine that screens for approximately 400 genetic diseases that have available treatment options. Called BeginNGS™ (pronounced “beginnings”), the program has enlisted a Who’s Who of partners in the diagnostic, genetic analysis, and rare disease drug development fields including Alexion, AstraZeneca’s Rare Disease group; Fabric Genomics; Genomemon; Illumina; and TileDB. Continue Reading….
G2 Intelligence | Agilent and Genomenon team up to bring users more effective software and search tools for making a genetic diagnosis. On June 7, genomic health IT company Genomenon announced it has partnered with analytical instrument manufacturer Agilent to give diagnostic labs a more effective tool for genomic variant interpretation. Continue Reading….
GenomeWeb | Genomenon said Tuesday that it will integrate its Mastermind Genomic Search Engine into Agilent Technologies’ Alissa Interpret genomic data analysis and variant interpretation software as part of a newly formed partnership. Continue Reading….
June 6, 2022 – Curation of the Entire Human Genome Requires the Best of Both Human and Artificial Intelligence
Technology Networks | The recent publication of the gapless, telomere-to-telomere human genome assembly serves as a real reminder of the significant work that remained to be completed from initial draft genome to the final sequence assembly. Similarly, while we have learned much about causative genetic variants in human disease over the past many years, there is much work that remains to complete this knowledge and to put it into practice. Continue Reading….
PRWeb | Genomenon Inc., an AI-driven genomics company, today announced that Bio-IT World has awarded them Best of Show for Disease-Specific Curated Content, now in the Mastermind Genomic Search Engine. Genomenon’s offering was one of 27 products considered for this prestigious award at last week’s Bio-IT World Conference & Expo in Boston. Continue Reading….
Crain’s Detroit Business | Genomic testing software company Genomenon Inc. has closed on $20 million in a Series B raise led by Farmington Hills-based venture firm Beringea, with money from other in-state and out-of-state investors. The capital raise by the 8-year-old Ann Arbor company, a University of Michigan spin-out, aims to expand Genomenon’s commercial operations. The company’s artificial intelligence-driven data search engine, called Mastermind, serves genetic testing labs, hospitals, pharmaceutical and biopharma companies. Continue Reading….
The Pathologist | The ultimate vision is to do newborn screening with next-generation sequencing for every baby that is born. To achieve this, we need to change our outlook on the world of genomics. It can’t cost a thousand dollars to sequence each genome, followed by thousands of dollars’ worth of experts perusing research papers to find evidence for each variant. Continue Reading….
Outsourcing Pharma | The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition. Continue Reading….
February 23, 2022 – Genomenon Partners with Don’t Forget Morgan to Provide New Hope for Rare Disease
Healthcare Tech Outlook | Genomenon, Inc., recently announced a partnership with Don’t Forget Morgan, a nonprofit support organization focused on rare disease patients living with Beta-Propeller Protein-Associated Neurodegeneration (BPAN), a progressive disease causing abnormal iron deposits in the brain leading to profound developmental delays The goal of this collaboration is to provide resources to assist researchers and encourage pharmaceutical companies to invest in finding effective treatments for BPAN, as well as empower patient care teams with actionable genetic information. Continue Reading….
GenomeWeb | Genomenon said Tuesday that it has partnered with a charity to identify variants that could help unravel the mystery of a rare pediatric disease. The firm hopes that the collaboration will lead to the development of treatments for beta-propeller protein-associated neurodegeneration, or BPAN, a progressive disease that causes severe developmental delays due to abnormal iron deposits in the brain. Continue Reading….
BioSpace | Genomenon announced Tuesday that it was awarded a $1.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health to help it organize and connect patient DNA to global genomic research in the areas of rare genetic diseases and cancer. The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year. Continue Reading….
Clinical Lab Manager | The sequencing of the human genome allowed scientists to reliably detect genetic variants in any gene and to understand their role in causing human disease. For clinical practice, though, retrieval and use of this information could only come through a painstaking process of evidence curation highly dependent on results published in the scientific literature. Continue Reading….
GenomeWeb | Genomenon said Tuesday that it has received a $1.7 million grant from the US National Institutes of Health’s Small Business Innovation Research (SBIR) program to accelerate development of the firm’s variant interpretation engine. Continue Reading….
January 31, 2022 – Health Tech: Mike Klein On How Genomenon’s Technology Can Make An Important Impact On Our Overall Wellness
Authority Magazine | In recent years, Big Tech has gotten a bad rep. But of course, many tech companies are doing important work making monumental positive changes to society, health, and the environment. To highlight these, Authority Magazine started a new interview series about “Technology Making An Important Positive Social Impact”. In this latest interview, Genomenon’s CEO, Mike Klein, speaks to his experience as a leader in tech, and explains how Genomenon provides the tools and data needed to inform a medical diagnosis from patients’ genetic data. Continue Reading….
Healthcare Tech Outlook | Following a year of 125% revenue growth, Genomenon, an AI-driven genomics company, today announced that Sean Kearney has been appointed Chief Financial Officer (CFO), effective immediately. As a valuable member of Genomenon’s executive leadership team, Mr. Kearney will lead the company’s financial operations. Continue Reading….
GenomeWeb | Genomenon said Tuesday that it will integrate its Mastermind genomics literature search engine into OmniTier’s CompStor Insight platform, a specialized appliance for tertiary analysis of next-generation sequencing data. The partnership will give CompStor Insight users a list of published articles relevant to their searches and help them quickly find the scientific evidence in Mastermind, the companies said. Continue Reading….
January 5, 2022 – Genomenon and OmniTier Partner to Bring Mastermind’s Evidence Sources to CompStor Insight
Healthcare Tech Outlook | “We are excited to announce a partnership with OmniTier, an organization that is bringing down the cost of genomic analysis for mainstream clinical diagnosis and screening centers.” said Mike Klein, CEO of Genomenon. “With this partnership, OmniTier’s CompStor Insight users will be able to directly link out to relevant Mastermind articles when investigating specific variants of interest.” Continue Reading….
Clinical OMICS | Genomenon’s Mastermind data analytics tool has indexed the full text of millions of scientific articles and prioritizes searches to generate the most relevant results many times faster. “We are on a mission to curate the entire human genome,” says Genomenon CEO Mike Klein. The company has indexed 8.3 million articles so far, and adds about 10,000 articles per week. Its algorithms are AI-informed. Any search can turn up between zero to tens of thousands of hits. “It’s very powerful to find zero hits,” Klein adds. Continue Reading….
November 18, 2021 – Genomenon and Inozyme Pharma Announce Partnership to Advance Genetic Diagnosis for Rare Patients
Healthcare Tech Outlook | Genomenon, Inc., an AI-driven genomics company, announced a partnership with Inozyme Pharma to make critical information readily accessible to genetic testing labs and clinicians. This information will help inform diagnosis and thus treatment decisions in patients with ENPP1 Deficiency, a rare disease also known as generalized arterial calcification of infancy (GACI) or autosomal recessive hypophosphatemic rickets Type 2 (ARHR2). Continue Reading….
Clinical Lab Manager | Genomenon, Inc., an AI-driven genomics company, announced a partnership with Inozyme Pharma to make critical information readily accessible to genetic testing labs and clinicians. This information will help inform diagnosis and thus treatment decisions in patients with ENPP1 Deficiency, a rare disease also known as generalized arterial calcification of infancy (GACI) or autosomal recessive hypophosphatemic rickets Type 2 (ARHR2). Continue Reading….
GenomeWeb | Genomenon said Thursday that it has formed a partnership with Inozyme Pharma to deliver molecular diagnostic data on a rare pediatric-onset calcification disorder to testing laboratories and clinicians. The collaboration aims to improve the diagnosis and treatment of ENPP1 deficiency, also known as generalized arterial calcification of infancy or autosomal recessive hypophosphatemic rickets Type 2. Continue Reading….
New technologies such as gene editing and genomics place drug discovery on the front line of a transformation in data management. Genomenon focuses on genomics research, which has experienced explosive growth in data generation. The company uses artificial intelligence to implement a genomics search engine for clinical research and a genomics database called Genomic Landscapes for drug discovery, says CEO Mike Klein. “We ID any variant ever published in association with a disease. We curate those and provide an interpretation with the scientific evidence that goes with it,” Klein says, describing Genomic Landscapes. Continue Reading….
GenomeWeb | Genomenon said Thursday that it has entered into a data partnership with Deep 6 AI, a maker of artificial intelligence-based clinical trial acceleration software. Under what the firms dubbed a proof-of-concept agreement, they will effectively explore combining their technology in search of insights about conditions including cancer, Parkinson’s disease, and Wilson’s disease, according to a spokesperson for Ann Arbor, Michigan-based Genomenon. Continue Reading….
October 22, 2021 – Alexion Partners with Genomenon to Deliver Detailed, Curated Variant Data to Speed Diagnosis
Diagnostics World | Most rare diseases have a genetic component, yet most people with rare diseases remain undiagnosed, Thomas Defay, Alexion Pharmaceuticals, told the audience at the Bio-IT World Conference & Expo last month. Thankfully, more and more patients with rare diseases are getting sequenced. At the Bio-IT World conference, Defay focused on the first two goals and highlighted Genomenon’s Mastermind product as the essential tool helping the company better capture existing scientific knowledge and then communicate the most relevant data to healthcare providers. Continue Reading….
September 27, 2021 – A Comprehensive Genomic Landscape for Amyotrophic Lateral Sclerosis (ALS) to Support Precision Medicine Initiatives
The Journal of Precision Medicine | To address the need for a comprehensive view into the literature, Genomenon has used a combination of Artificial Intelligence (AI) and expert curation to produce a Genomic Landscape for ALS – a comprehensive collection of every published variant in 36 ALS-associated genes, interpreted according to the American College of Medical Genetics (ACMG) criteria for assessing variant pathogenicity. The identification and accurate interpretation of any of these variants could conceivably aid in early diagnosis, perhaps even before symptom onset, and subsequent targeted treatment for ALS patients. Continue Reading….
September 26, 2021 – Genomenon Partners With Alexion To Help Genetic Testing Labs Diagnose Rare Diseases
MiTechNews | Genomenon, an AI-driven genomics company, announced it will collaborate with Alexion, AstraZeneca Rare Disease to make critical information needed for the diagnosis and treatment for a set of rare diseases more readily accessible. The goal of this collaboration is to empower genetic testing labs with the data they need to diagnose patients suffering from rare diseases. Continue Reading….
Fierce Biotech | AstraZeneca’s freshly minted subsidiary Alexion Pharmaceuticals has tapped the artificial intelligence startup Genomenon to help with its work in rare diseases. The collaboration will be aimed at genetic testing laboratories, with the goal of shortening the overall amount of time it takes for a definitive diagnosis, which at times can take several years and as many specialists. Continue Reading….
GenomeWeb | Working with Alexion, Ann Arbor, Michigan-based Genomenon will apply its artificial intelligence-driven technology to create what the firm calls a “genomic landscape” for specific conditions, including Wilson disease, complement-mediated thrombotic microangiopathy, lysosomal acid lipase deficiency, and hypophosphatasia. Alexion, which was acquired by AstraZeneca in July, and Genomenon may add other rare diseases to the collaboration in the future. Continue Reading….
Michigan Business Network | Genomenon, the AI-driven genomics company, recently announced that it will feature expert clinicians from Acibadem Labgen in Turkey and Héritas in Argentina at this year’s European Society of Human Genetics Virtual Conference. The on-demand talk will highlight the innovative Mastermind Genomic Search Engine, and how it has made a difference in real-life clinical cases. Continue Reading….
August 26, 2021 – Genomenon Hosts Clinical Genomics Experts at European Society of Human Genetics (ESHG) Conference; Acibadem Labgen and Héritas Describe Use of Genomenon’s Mastermind Genomic Search Engine to Solve Real-World Cases
bioquick News | Genomenon, an AI-driven genomics company based in Ann Arbor, Michigan, announced that it will feature expert clinicians from Acibadem Labgen in Turkey and Héritas in Argentina at this year’s European Society of Human Genetics Virtual Conference (August 28-31). The on-demand talk will highlight Genomenon’s innovative Mastermind Genomic Search Engine, and how it has made a difference in real-life clinical cases. Mastermind works by connecting patient genetic data with relevant evidence from scientific literature – essential to the practice of precision medicine for the diagnosis and treatment of cancer and genetic disease. Continue Reading….
Michigan Business Network | Genomenon has recently published a scientific report on the efficacy of comprehensive Genomic Landscapes for disease and their implications for drug discovery and development within Pharma. The report, entitled Key Findings from the Genomic Landscape for ALS, explores previously unknown insights into pathogenic variants and their functional consequence on disease presentation. Continue Reading….
GenomeWeb | Genomenon said Tuesday that it has partnered with German bioinformatics startup Nostos Genomics to integrate its Mastermind genomic search engine into the Nostos AIon AI-driven variant interpretation platform. According to Ann Arbor, Michigan-based Genomenon, this integration will allow AIon users to preview lists of published articles related to their searches from within the AIon interface. This, the companies said, will help improve diagnosis of rare genetic diseases. Continue Reading….
Healthcare Tech Outlook | Genomenon, an AI-driven genomics company, announced that it has published a new pharma report: Key Findings from the Genomic Landscape for ALS. Also known as Lou Gehrig’s disease, ALS is a rare neurodegenerative disorder that affects about five in 100,000 individuals and causes devastating motor, cognitive, and behavioral impairment. Furthermore, clinicians and researchers are faced with a frustrating shortage of actionable information, which results in limited genetic testing and few successful drug programs. Continue Reading….
Angel Capital Association | The prestigious Luis Villalobos Award, recognizing the most ingenious and innovative ideas recently financed by members of the Angel Capital Association, was recently awarded to two ACA member-funded companies disrupting their fields. Algenesis, a material science technology company, in the Technology, Services and Consumer category; and Genomenon, a genomic health IT company, in the Life Sciences category. The 2021 Luis Villalobos Award winners are changing the landscape in their respective spaces with ground-breaking innovations. Continue Reading….
aitechpark | Genomenon announced a partnership with Limbus Medical Technologies, which includes integration of the Mastermind® Genomic Search Engine into the cloud-based varvis® platform. In the initial integration available now, users of varvis can preview the number of published articles related to their search and easily link out to view the evidence in Mastermind. Continue Reading….
April 12, 2021 – Genomenon, Limbus Medical to Integrate Technologies for Clinical Variant Interpretation
GenomeWeb | Genomenon said Monday that it has partnered with Limbus Medical Technologies to integrate its Mastermind genomics literature search engine into Limbus’ Varvis, a genomics-based clinical diagnostics decision support system. Continue Reading….
TechCentury | Genomenon, the Ann Arbor-based genetics informatics company, has completed a $5.3 million financing round, company officials announced. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, hospitals, pharmaceutical and biopharma companies. Continue Reading….
Healthcare Tech Outlook | Genomenon announced that it has completed a $5.3 million financing round in the company. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, pharmaceutical and biopharma companies. Genomenon leverages AI (Artificial Intelligence) to organize the world’s genomic knowledge and put it at the fingertips of doctors and clinicians to diagnose patients suffering from rare & genetic diseases and cancer, and researchers to help create precision medicine targeted at molecular drivers of a disease. Continue Reading….
GenomeWeb | Genomenon said on Tuesday that it has raised $5.3 million in a financing round. The Ann Arbor, Michigan-based firm will use the funding to expand its global commercial operations, which serves genetic testing labs, hospitals, pharmaceutical, and biopharma companies. New investors include BroadOak Capital Partners, Green Park & Golf Ventures, Red Cedar Ventures, and Michigan Rise. Current investors, including Invest Detroit Ventures, IrishAngels, Michigan Angel Fund, Invest Michigan, and Atain Specialty Insurance, also participated in the round. Continue Reading….
dbusiness | Ann Arbor-based Genomenon, an artificial intelligence-driven genomics (a genome is an organism’s set of DNA) company, has entered into a collaboration with BC Platforms, a health care data management, analytics, and access company in Switzerland. Continue Reading….
February 23, 2021 – BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research
Global Genes | Healthcare data management company BC Platforms said it has entered a collaboration with AI-driven genomics company Genomenon to advance clinical genomics and research. Continue Reading….
GenomeWeb | BC Platforms and Genomenon said Tuesday that they have agreed to combine their technologies for rare disease diagnostics and research. The collaboration calls on Genomenon to integrate its Mastermind genomic search engine into two BC Platforms products: the BC|Genome genomic interpretation and analysis platform to support molecular diagnostics and other forms of clinical genomics; and discovery and insight system BC|Insight on the research side. Continue Reading….
Read the latest release from trusted integration partner Ensembl. In web VEP, users are provided links to results in Mastermind which reports gene, variant, CNV, disease, phenotype, and therapy evidence from millions of scientific articles. Continue Reading….
Michigan Business Network | Yesterday, Genomenon released news that a study conducted by their data scientists at Genomenon has been published in a prestigious peer-reviewed journal focused on advances in genomics. This seminal paper, published in the Computational Genomics section of Frontiers in Genetics, provides insight into how the innovative Mastermind Genomic Search Engine streamlines genomic variant interpretation by leveraging AI and machine learning. This evidence demonstrates how Mastermind manifests a critical paradigm shift within the realm of clinical practice. Continue Reading….
FirstWord MedTech | Genomenon, Inc., an AI-driven genomics company that connects the world’s genomic knowledge with patient DNA, announced that a seminal paper written by its team of scientists has been published in the Computational Genomics section of Frontiers in Genetics. Frontiers in Genetics is an open-access journal that publishes rigorously peer-reviewed research on genes and genomes relating to all domains of life. Continue Reading….
Healthcare Tech Outlook | Genomenon – Bolstering Precision Medicine with Genomics. “We are revolutionizing the way genomic information is searched, made available, and understood,” says Mike Klein, CEO of Genomenon. Continue Reading….
Tech Tribune | Genomenon has been featured as a 2021 Best Tech Startup in Ann Arbor by The Tech Tribune. For the fourth year in a row, Genomenon has received this recognition based on revenue potential, leadership, brand/product traction, the competitive landscape and more. Continue Reading….
October 2, 2020 – Clara Health, Genomenon and BrainBaseline Share How They’re Improving the Clinical Trial Process
Pharmaceutical companies need tools to help them more efficiently identify targets, find and enroll patients and monitor and study participants — all tasks that have been made even more challenging by today’s virtual-first world. To help address these challenges, we invited three MATTER startups to share their solutions, and the challenges they solve, to two of our pharmaceutical partners: Eli Lilly and Astellas. Continue Reading….
Advancements in personalized medicine via innovative data and analytic solutions continue to accelerate opportunities to support rare disease identification, treatment pathways and novel drug development. In the realm of rare and orphan diseases there are many unmet research needs related to therapeutic treatments. Genomenon’s work with Rhythm Pharmaceuticals and how we helped map their clinical development strategy is mentioned in this article from graticule. Continue Reading….
Genomenon announced today that CEO Mike Klein has been named to TechCEOs list of “Top 25 Biotechnology CEOs of 2020”. Klein was recognized for leading Genomenon, one of the most innovative health IT companies in genomics. Genomenon’s AI-powered genomic search engine is used by nearly 10,000 clinicians across 118 countries to diagnose rare disease patients from their DNA. Continue Reading….
After two years in the market, Genomenon has more than 8,000 users at hospitals, genetic testing labs and pharmaceutical companies in 115 countries, said CEO Mike Klein. Read more about Genomenon’s challenges and success during an unprecedented time in our industry. Continue Reading….
Billions of dollars are spent on medical research every year. However, gaining access to that information is a bit easier said than done. In this episode of Bottom Line IT, host Mike Maddox of ASK sits down with Mike Klein who is the CEO of Genomenon. Continue Reading….
Machine learning is being applied across the industry to support decision-making in clinical trials, R&D, regulatory, and commercial processes. Co-founder and CSO, Dr. Mark Kiel is an industry contributor in this article in PharmaVOICE. Continue Reading….
With a wealth of experience in building and running information technology companies, Mike Klein brought his expertise into the rare disease world and in particular genomic medicine, when he joined Genomenon as CEO. He talks to RARE Revolution about the impact technology is having on diagnosing rare diseases and contributing to drug development, and about the exciting potential that lays ahead. Continue Reading….
Genomenon is proud to be the variant interpretation tool that leading clinical decision support platforms use to provide easy access to the most comprehensive collection of published genomic evidence. Today we celebrate our 13th integration with eVai, created by enGenome. Continue Reading….
Genomenon’s Mastermind Genomic Search Engine has been integrated into the eVai Variant Interpretation platform from EnGenome, Genomenon said. eVai users can now preview the number of published articles related to their search and easily link out to view the evidence in Mastermind. Continue Reading….
Just announced! Mastermind Genomic Search Engine users can now search by therapy & query the comprehensive database of genomic evidence for over 180,000 drugs, therapies and other interventions! Continue Reading….
An exclusive Tech Tribune Q&A with Steve Schwartz, the co-founder and Chief Technology Officer of Genomenon, which was honored in our: 2020 Best Tech Startups in Ann Arbor, 2019 Best Tech Startups in Ann Arbor, 2018 Best Tech Startups in Ann Arbor. Continue Reading….
An exclusive Tech Tribune Q&A with Mark Kiel, the co-founder and Chief Science Officer of Genomenon, which was honored in our: 2020 Best Tech Startups in Ann Arbor, 2019 Best Tech Startups in Ann Arbor, 2018 Best Tech Startups in Ann Arbor. Continue Reading….
March 19, 2020 – Something to Smile About: The Journey Toward a Cure with Rare Disease Foundation NFED
Genomenon was featured in The Journal of Precision Medicine about our work with The National Foundation for Ectodermal Displasias (NFED). Continue Reading….
Genomenon commended by Frost & Sullivan for Advancing Clinical Genomics Interpretation and personalized medicine with its Mastermind Platform. Continue Reading….
January 8, 2020 – Going Beyond The Pill: Digital solutions driving pharma commercialization and improving patient outcomes
Genomenon was featured in the First Analysis report listed as a notable digital tool for A.I. and Drug Discovery. Continue Reading….
Genomenon, Ann Arbor, Mich, has released Mastermind version 2.0. The genomic search engine now includes the ability to search the entirety of the genomic literature by phenotype (symptoms), a feature that will accelerate diagnosis of patients with genetic and rare diseases. Continue Reading….
Sarah Chisolm didn’t want to start a rare disease foundation – she had to. Her life changed forever when her daughter was diagnosed with beta-propeller protein-associated neurodegeneration, or BPAN, a rare genetic condition caused by mutations in the WDR45 gene. Continue Reading….
December 16, 2019 – BPAN Warriors: A Rare Disease Community’s Search for Connection, Collaboration and a Cure
Platforms such as Genomenon and Mastermind provide patient communities, researchers and industry the ability to rapidly assimilate information. Through the use of increasingly complex and accurate mathematical models and algorithms, large amounts of information, potentially across diseases communities, can now be collected, analyzed and distilled into usable datasets. Continue Reading….
The addition of Mastermind will enable Congenica users to quickly access the genetic evidence associated with their patients’ variants, shortening the search time required to clinically interpret a variant and support its pathogenicity. Continue Reading….
The Ann Arbor-based genetic research software developer Genomenon Inc. announced the release of version 2.0 of its Mastermind software. The genomic search engine now includes the ability to search the entirety of the genomic literature by phenotypes (symptoms). This new functionality will further accelerate diagnosis of patients with genetic and rare diseases. Continue Reading….
November 6, 2019 – Genomenon Releases Updated Search Engine to Accelerate Rare and Genetic Disease Diagnosis
Genomenon has released an updated version of its Mastermind genomic search engine that now includes the ability to search the entirety of the genomic literature by phenotypes, or symptoms that it says will further accelerate diagnosis of patients with genetic and rare diseases. Continue Reading….
“This partnership will help experts better and more quickly assess the impact of accurately detected genomic variants in a clinical context,” said Gioia Althoff, senior vice president, genomics for SOPHiA, in a press release. We are thrilled to be able to provide our users with all the necessary information they need to make the best possible decision for each case. Continue Reading….
October 15, 2019 – Sophia Genetics, Genomenon Integrate Artificial Intelligence, Genomic Data Software
Genomenon announced today it has partnered with Sophia Genetics to incorporate the Mastermind Genomic Search Engine into the Sophia artificial intelligence platform and Alamut Suite. Under the new partnership, users will be able to apply both technologies to rapidly access genomic evidence linked to human variants, reducing the time needed to interpret a variant and examine its pathogenicity. Continue Reading….
October 10, 2019 – NHS to Benefit as Congenica Adds Two Major Data Sources to Genomic Medicine Platform
Congenica is integrating two powerful sources of data into its genomic medicine platform, which will help clinicians in the NHS using it to diagnose disease. The Wellcome Genome Campus-based digital health technology company is adding data from DECIPHER and Mastermind to its software. Used to support clinical decisions, Congenica’s software accelerates the interpretation of complex genomic data. Continue Reading….
October 4, 2019 – Congenica to Integrate Genomenon’s Mastermind into its Clinical Decision Support Tool
Two new reference data sources, Mastermind and DECIPHER, are being added to Congenica’s clinical decision support platform for genomic data interpretation. Genomenon’s Mastermind, which is used by hundreds of genetic labs worldwide, has indexed nearly 7 million full text articles and 500,000 supplemental data sets and covers over 4.9 million variants found in the medical literature. DECIPHER contains disease-causing variants from over 33,000 rare disease patients. Continue Reading….
Congenica and Genomenon said today that they have partnered to incorporate Genomenon’s Mastermind Genomic Search Engine results into Congenica’s clinical decision support platform. Congenica, based in Cambridge, UK, markets software that enables the analysis and interpretation of genomic data to help healthcare professionals make more rapid and accurate diagnoses. Continue Reading….
Keck Graduate Institute and Genomenon are helping shape the future of precision medicine by training new variant scientists with the most advanced tool, including Mastermind, to address the challenges of variant interpretation, today and tomorrow. Continue Reading….
Genomenon uses Artificial Intelligence (AI) and Machine Learning (ML) to accelerate the literature curation process in Mastermind, the most comprehensive database of genomic information in the world. Mastermind scans the titles and abstracts of the entire scientific literature comprising over 30 million scientific papers, selecting them for genomic information. Continue Reading….
Ann Arbor, Michigan-based Genomenon said today that the new partnership will allow the company to bring its Mastermind genomic search engine to clinical laboratories in China. “Our partnership with Shanghai Shanyi will allow us to expand our footprint in the China market, seamlessly integrating with their other best-of-breed end-to-end clinical [next-generation sequencing] solutions,” Genomenon CEO Mike Klein said in a statement. Continue Reading….
Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory had failed in securing diagnosis for an ultra-rare disease patient. Romina Ortiz, Chief Operating Officer and Vice President, Patient Advocacy at the Institute explains how the platform could prove transformative in tackling the challenges of ultra-rare disease diagnosis. Continue Reading….
August 6, 2019 – Genomenon Wins SBIR Grant to Develop ‘Micropublications’ for Variant Interpretation
Genomenon said today it has won a Small Business Innovation Research (SBIR) grant from the NIH’s National Human Genome Research Institute (NHGRI). Funding from the grant, valued at $152,946, will go toward creating a platform for producing and sharing “micropublications” across the genomics research community, as well as continuing Genomenon’s efforts to automate variant interpretation based on data from published studies. Continue Reading….
Well over 20,000 fusion genes have been documented since the first one was discovered in 1973…says Mark Kiel, MD, PhD, founder and chief science officer of Genomenon. Mastermind organized all the evidence (roughly 30,000 articles) on the 507 “bad actor” genes comprising the Illumina TruSight Fusion Gene Panel. It then compiled a list of the well-known fusion partners—numbering between one and 95—involved in 2,500 fusion events in those genes in a new report… Continue Reading….
Genomenon, a leading genomic research company, was honored with a Best of Show award at the Bio-IT World Conference & Expo in Boston. The prestigious award recognizes the best in innovative life sciences industry product solutions, in this case Genomenon’s Mastermind Genomic Search Engine. A panel of experts from academia, industry, pharma and biotech, bases their judgement on uniqueness, importance to the industry, and the ability to offer a compelling return on investment. Continue Reading….
Keck Graduate Institute (KGI) has become the first academic partner in a new genomics education program launched by Genomenon, creator of the Mastermind genomic search engine providing search results from the full-text database of 6.5 million genomic-focused scientific articles. “We feel strongly that Mastermind is the best way to interpret variants and make clinical decisions more quickly. We realized that schools like KGI are the future of genomics. We’re partners in equipping the next generation of genomic scientists,” says Candace Chapman, director of marketing for Genomenon, a privately held company founded in Ann Arbor, Michigan, in 2014.” Continue Reading….
Genomenon announced today the launch of its Genomics Educator Program and named the Keck Graduate Institute(KGI) as its first academic partner for this effort which provides graduate level students with access to its flagship product the Mastermind Genomic Search Engine. According to Candace Chapman, director of marketing for Genomenon, the relationship with KGI was built off a conversation struck up between Fortini and Genomenon executives in 2017 at the American Society of Human Genetics (ASHG)Annual Conference. “Barbara has shared great feedback as a Mastermind user since then, and she was the first person we reached out to for the Genomic Educator’s Program,” Chapman told Clinical OMICs in an exclusive interview. “It’s safe to say that Barbara and the Keck program was a major inspiration.” Continue Reading….
“Sometimes there is only one research paper that can connect a patient’s DNA with a diagnosis. Searching through millions of research papers to find a patient’s genetic mutation can be like trying to find a needle in a haystack. With advanced AI techniques used by Genomenon, the needle can pop right into view.” said Dr. Ray. “I can say with certainty that without the findings obtained from Genomenon, I would not have been able to provide a diagnosis for this patient.” Continue Reading….
Jeffrey Mosher talks with Mike Klein, CEO of one of Michigan 50 Companies to Watch in 2019, Genomenon, Ann Arbor, MI. Mike Klein with over 25 years of developing, building and growing 4 different high tech companies. In fact Genomenon is the third company Mike has led to being honored by the Michigan 50 Companies to Watch category! Genomenon has replaced the manual search process in gene and variant interpretation with a genomic search engine and database of all the disease-gene-variant relationships found in the full text of the scientific literature. Our technology is revolutionizing the way genetic diagnoses and discoveries are made by making it easier to get rapid insight into prioritized, clinically relevant literature for both clinical decision making and research projects. Continue Reading….
April 18, 2019 – BioIT World Conference Highlights: Altos and WASAI, Genomenon and Google, 1 CellBio and More
The BioIT World Conference & Expo is going on in Boston, Massachusetts, highlighting companies and breakthroughs working on the data end of life sciences, whether that’s blockchain, artificial intelligence, machine learning, data science, deep learning or others. Here’s a sample of some of the stories out of the conference. Genomenon Partners with Google for Genomic Data Continue Reading….
Today BIO-IT World announced the 2019 winners of the Best of Show Awards Program to a packed audience at the BIO-IT World Conference & Expo. The awards program recognizes the best of the life sciences industry on display at the BIO-IT World Conference & Expo in Boston. “The innovation on display by BIO-IT World exhibitors never disappoints,” said BIO-IT World Editor Allison Proffitt. “It’s always a treat to see the work and dedication from companies firsthand, and we are excited to shine a spotlight on the best life sciences has to offer.” Continue Reading….
Genomenon, the Ann Arbor-based genomics information provider, has announced a partnership with Google to make the company’s genomic mutation data available on Google Cloud platform. Genomenon’s Cite Variants Reference (CVR) data will be a public dataset available in BigQuery, Google Cloud’s big data and machine learning data warehouse, for use in genomic applications. Continue Reading….
Genomenon’s Mastermind Genomic Search Engine has been selected as a Bio-IT Best of Show finalist. A team of expert judges views entries on site and chooses winners in four categories based on the product’s technical merit, functionality, innovation, and in-person presentations. Continue Reading….
April 8, 2019 – Revolutionizing Genomics, How a Tech Company is Empowering Personalized Medicine by Directing Information Straight to Doctors’ Fingertips
Genomenon is a DNA interpretation software company that was born out of the growing gap between big data and diagnostic decision-making. The field of genomics and DNA sequencing was unimaginable 25 years ago. The real challenge now is making that information practical, and that’s the niche in which… Genomenon fits. Continue Reading….
LifeMap Sciences will integrate Genomenon’s Mastermind Genomic Search Engine into its GeneCards knowledgebase, the companies announced today. The partnership will help researchers using GeneCards more easily identify relevant literature associated with genes, diseases, and variants, according to the firms. Continue Reading….
It is said that this is the best of times for direct to consumer (DTC) genetic testing companies, human disease genomics, and the launch of genomic data marketplaces. Due to advances in technology and the availability of cost-effective consumer genotyping kits, massive genomic data sets from human patients and controls are being created from across nations. As a result, it is not only the continued growth in the number of disease genes identified, but it will also advance a deepening of our understanding of the fundamental human genetic architecture and disease states. Moreover, we will also see the commercialization of genomic data. Continue Reading….
The Rare Genomics Institute, a nonprofit organization providing support to undiagnosed rare disease patients, announced on Rare Disease Day 2019 that they had used the Mastermind Genomic Search Engine, a clinical decision support tool by Genomenon, to diagnose a rare disease patient. We spoke to Mark Kiel, MD, PhD, Founder and Chief Science Officer at Genomenon and Romina Ortiz, COO at the Rare Genomics Institute, to learn more about the application of this technology in rare diseases. Continue Reading….
Rare Genomics Institute said today it successfully diagnosed a previously undiagnosed patient using Genomenon’s Mastermind Genomic Search Engine.The announcement, timed to coincide with Rare Disease Day 2019, comes four months after the partners launched a collaboration in which Genomenon agreed to donate licenses allowing clinical scientists working with Rare Genomics Institute to access Mastermind. Continue Reading….
February 23, 2019 – AI-Based Software Provider and Genomic Search Company Partner to Improve Rare Disease Diagnostics
Diploid, an artificial intelligence (AI)-based software provider for rare disease diagnostics, and Genomenon, a genomic search company, are partnering to improve genome interpretation for rare disease diagnostics. Genomenon’s Mastermind Genomic Search Engine filters and prioritizes millions of articles about genomics to find the most useful and meaningful citations. The search engine saves scientists hours of literature curation per case, and improves the chances of finding key genetic information that could be critical for a patient’s diagnosis. Continue Reading….
Diploid announced that its Moon software, which is focused on rare disease diagnostics, will integrate Genomenon’s Mastermind Genomic Search Engine. The companies said their goal is to improve genome interpretation by giving direct access to Mastermind from Moon’s user interface. Continue Reading….
Genomenon said today that it has partnered with artificial intelligence software firm Diploid to improve genome interpretation for rare disease diagnostics. As part of the collaboration, Belgium-based Diploid will integrate Genomenon’s Mastermind genomic search engine into its Moon diagnostic software. Continue Reading….
Mastermind is now used by more than 2,200 clinicians in 35 countries and 200 labs. “We’ve been able to demonstrate we got the business model right, now it’s time to add fire with more investment in sales and marketing. We’re at the precipice of three key technologies: big data, A.I., and cloud computing. Continue Reading….
ANN ARBOR – Genomic search company Genomenon has hired industry veteran David Anstey as Vice President of Sales. In his new role at Genomenon, Anstey is responsible for building out and leading the company’s sales and business development efforts. “Dave brings 20 years of experience selling into life science companies, and he has an excellent track record of driving growth and building partnerships with his customers” said Mike Klein, CEO of Genomenon. “We’re excited to have Dave join our team and help drive our success.” Continue Reading….
The Tech Tribune staff has named Genomenon to the list of the Top Ten Tech Startups in Ann Arbor, Michigan. Selection criteria included revenue potential, leadership team, brand/product traction, and competitive landscape. This is the second year in a row that Genomenon was honored. Continue Reading….
November 27, 2018 – Genomenon announced that it has published the first Cited Variant Reference (CVR)
This first-in-kind Cited Variant Reference contains over 3.7 million genomic variants found in medical literature. Each variant is annotated with a citation count based on the number of scientific publications mentioning the variant, along with a link into the Mastermind® Genomic Search Engine to view full search results for those articles. Continue Reading….
Genomenon announced that it has published the first Cited Variant Reference (CVR), a comprehensive catalogue of genetic variants cited in the medical literature. The term “variant” refers to a genomic mutation in the DNA – key data used in searching for causes of cancer and rare diseases. Continue Reading….
GenomOncology will integrate into its Molecular Tumor Board platform results from Genomenon’s Mastermind Genomic Search Engine, through a collaboration whose value was not disclosed.The companies said their critically ilpartnership was designed to enable oncologists to access up-to-date genomic research Continue Reading….
October 29, 2018 – Clinical Genomic Literature Search Partnership Formed by Genomenon, GenomOncology
Genomenon and GenomOncology announced today that they have formed a partnership to incorporate Genomenon’s Mastermind search engine into GenomOncology’s Molecular Tumor Board software, in order to help oncologists make more informed clinical decisions. Continue Reading….
October 18, 2018 – Genomenon Partners with Rare Genomics Institute, Begins with Philanthropic Donation
Genomenon announced today that they will donate Mastermind Genomic Search Engine licenses to the entire team of clinical scientists at Rare Genomics Institute to accelerate their work for patients with rare diseases. Continue Reading….
October 18, 2018 – Fabric Genomics and Genomenon Sign Partnership Agreement to Speed Genomic Interpretation
Fabric Genomics™, a global leader in clinical interpretation of genomic data, and Genomenon®, the leading genomic data search company, announced today that they have entered into a partnership with the goal of further strengthening clinical genomic interpretation and variant classification. Continue Reading….
Fabric Genomics and Genomenon announced today that they have signed an agreement to integrate their respective genomic interpretation technologies and co-market the combined offering. Continue Reading….
They call it the Valley of Death for a reason. Entrepreneurs coined the term to describe the period from when a startup is formed to when it generates revenue. Research shows that nearly 90 percent of startups fail — a stark statistic that University of Michigan alumnus Mark Kiel knows well. Continue Reading….
All About AI, Michigan’s largest conference on entrepreneurship, presented by TiE Detroit, today announced the winners of the TiE20 Industry Awards. Selected from more than 500 nominated companies, the winners represent the most enterprising startup companies. Continue Reading….
After a successful proof-of-concept study in 2017, Genomenon is well into its work under a two-year, $1.5 million National Institutes of Health grant to add artificial intelligence to variant interpretation. Continue Reading….
July 31, 2018 – Genomenon in Ann Arbor Awarded NIH Grant to Further Scale the Adoption of Genomic Sequencing
Ann Arbor-based Genomenon, a leading genomic data search company that operates the world’s only comprehensive genomic-specific search engine, today announced it was awarded a Phase 2 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). Continue Reading….
Genomic Data Search company Genomenon has been awarded a Phase 2 Small Business Innovation Research grant by the National Institutes of Health. The grant will be used to develop and apply machine learning and artificial intelligence algorithms to variant interpretation, the single biggest hurdle in scaling the adoption of genomic sequencing in both clinical and precision medicine applications. Continue Reading….
Collaborations have long produced some of the most significant developments and discoveries in science, art and engineering. It’s not just people either. Huge benefits can come from businesses doing the same. I’ve taken a look at 5 collaborations that are doing just that. Continue Reading….
The Ann Arbor, MI, startup focused on analyzing genomics data to guide clinicians in the diagnostic process, last week announced its newest partnership. The company has entered into a co-marketing agreement with San Francisco’s Fluidigm, which develops, manufactures, and markets analytical systems with life sciences applications. Continue Reading….
The companies have signed a co-marketing agreement to create a joint panel design offering intended to help researchers accelerate the design of disease-specific next-generation sequencing (NGS), genotyping, and real-time PCR panels for use with Fluidigm’s automated microfluidic systems. Continue Reading….
Joint offering enables acceleration of genomic panel design for translational and clinical disease research Joint offering enables acceleration of genomic panel design for translational and clinical disease research. Continue Reading….
Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease research. Continue Reading….
Fluidigm has announced that it has entered a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease researchers. Continue Reading….
Swift Biosciences and Genomenon said today that they have entered a new partnership in which they will co-market a service for the design and creation of targeted gene sequencing panels. Continue Reading….
May 22, 2018 – Learning the Literature: Genomenon, Veritas Collaborate on Next-Gen Publication Prioritization Engine
Genomenon has announced it will partner with Veritas Genetics to develop a next-generation literature prioritization engine the companies said will further scale the global adoption of whole-genome sequencing by reducing the time and cost of variant interpretation. Continue Reading….
Apr 26, 2018 – Ann Arbor’s Genomenon, a startup focused on genomic search data, has struck a new partnership with Boston’s Rhythm Pharmaceuticals
Genomenon and Rhythm will team up to create a database of genetic mutations associated with obesity as documented in the medical literature. Genomenon has developed Mastermind, a genomic search engine that connects genomic data with evidence from scientific literature. Continue Reading….
Genomenon said today it has partnered with Rhythm Pharmaceuticals to create a database of genetic mutations associated with obesity as documented in published studies. Rhythm plans to use the data to better understand rare genetic disorders of obesity. Continue Reading….
Genomenon announced Mastermind Genomic Search Engine users can accelerate their genomic interpretation by searching the scientific literature that fits each individual ACMG classification criteria. Continue Reading….
Genomenon will partner with Veritas, The Genome Company, to develop a next-generation literature prioritization engine designed to further scale the global adoption of whole genome sequencing by reducing the time and cost of variant interpretation. Continue Reading….
DNA sequencing company Veritas Genetics is partnering with genomic literature search engine Genomenon in an effort to move literature prioritization forward with the help of artificial intelligence. Continue Reading….
GenomeNext has embedded within its Olympus genomic analysis platform results from Genomenon’s Mastermind Genomic Search Engine, through a partnership aimed at accelerating variant curation for genomic analysis. Continue Reading….
Integrating Mastermind with GenomeNext’s Olympus Platform dramatically improves and accelerates variant curation, further streamlining automation of genomic analysis and interpretation. Continue Reading….
Genomenon’s Mastermind genomic search engine now includes links to Saphetor’s VarSome genomic annotation tool. In turn, VarSome, which contains curated data from more than 30 publicly available genomic databases, has Mastermind links to scientific literature related to each variant and gene. Continue Reading….
Jan 1, 2018 – Genomenon Illuminates Current Trends in Genomic Literature – Top 10 Cited Variants in 2017
Mastermind Genomic Search Engine Dives into Current Trends in Genomic Variant Research – A Look at the Top Cited Variants Across the Scientific Literature. Continue Reading….
Genomenon, a University of Michigan spinout developing analytics and data visualization software for the genomics industry, last week announced it has created an evidence-based cancer gene panel using automated machine learning techniques. Continue Reading….
Dr. Mark Kiel, MD PhD, Founder and Chief Scientific Officer of Genomenon Shares His Views on Diagnostic Genomics in Risk Roundup Interview. Continue Reading….
Genomenon, developing analytics and data visualization software for the genomics industry, released its first product last week: The Mastermind Genomic Search Engine. Continue Reading….
Mike Klein, a veteran of the Ann Arbor tech scene, was named CEO of Genomenon, a spinoff from the University of Michigan that creates genome interpretation software to speed patient diagnosis using personalized medicine. Continue Reading….
The University of Michigan’s Monroe-Brown Biomedical Seed Fund announced inaugural investments in two biotech startups spun out of the university. Continue Reading….
Like a lot of tech startups, Ann Arbor-based Genomenon has a name that’s a little hard to say and a suite of products that’s hard for non-techies to understand. What’s clear is Genomenon’s … Continue Reading….
NEW YORK (GenomeWeb) – Genomenon, an Ann, Arbor, Michigan-based startup focused on developing tools for the personalized medicine space, is currently recruiting early adopters to test-drive … Continue Reading….
When Steve Schwartz went up to collect the ceremonial $100,000 check for taking second place at the Accelerate Michigan Innovation Competition last week, he was surprised but not shocked. Continue Reading….
Genomenon Inc., a University of Michigan spinoff that is being incubated in the office of technology transfer’s Venture Accelerator on the north campus, has closed an investment round of $1 million. Continue Reading….
Each of the Healthcare finalists presented their ideas to a panel of expert judges for a chance to win $1 million and work with Verizon to turn their idea into a reality. Continue Reading….
Three U-M pathologists who developed software that could improve cancer diagnosis and treatment have won a statewide entrepreneurship competition … Continue Reading….